Qualigen Therapeutics, Inc. Announces management changes.
Qualigen Therapeutics, Inc. (NASDAQ: QLGN) announced significant management changes on September 26, 2024. Michael Poirier resigned as CEO and Chairman of the Board, while Christopher Lotz stepped down as CFO, both effective immediately. Their resignations were due to disagreements over the company's future direction and strategic initiatives.
The Board appointed Campbell Becher as President on September 25, and Kevin Richardson as Interim CEO and CFO, as well as a board member, on September 26. Richardson, known for his experience in leading strategic and turnaround efforts in small cap companies, expressed excitement about enhancing shareholder value through new strategic initiatives. Becher echoed this sentiment, acknowledging the potential opportunities ahead for Qualigen.
Qualigen Therapeutics, Inc. (NASDAQ: QLGN) ha annunciato significativi cambiamenti nella gestione il 26 settembre 2024. Michael Poirier si è dimesso da CEO e Presidente del Consiglio di Amministrazione, mentre Christopher Lotz ha lasciato il ruolo di CFO, con effetto immediato. Le loro dimissioni sono avvenute a causa di disaccordi sulla direzione futura dell'azienda e sulle iniziative strategiche.
Il Consiglio ha nominato Campbell Becher come Presidente il 25 settembre, e Kevin Richardson come CEO e CFO ad interim, oltre a membro del Consiglio, il 26 settembre. Richardson, noto per la sua esperienza nella guida di iniziative strategiche e di risanamento in aziende di piccole dimensioni, ha espresso entusiasmo per il miglioramento del valore per gli azionisti attraverso nuove iniziative strategiche. Becher ha condiviso questo sentimento, riconoscendo le potenziali opportunità future per Qualigen.
Qualigen Therapeutics, Inc. (NASDAQ: QLGN) anunció cambios importantes en la administración el 26 de septiembre de 2024. Michael Poirier renunció como CEO y Presidente de la Junta, mientras que Christopher Lotz dejó su puesto como CFO, ambos con efecto inmediato. Sus renuncias se debieron a desacuerdos sobre la dirección futura de la empresa y las iniciativas estratégicas.
La Junta nombró a Campbell Becher como Presidente el 25 de septiembre, y a Kevin Richardson como CEO y CFO interino, así como miembro de la Junta, el 26 de septiembre. Richardson, conocido por su experiencia en liderar esfuerzos estratégicos y de reestructuración en empresas de pequeña capitalización, expresó su entusiasmo por aumentar el valor de los accionistas a través de nuevas iniciativas estratégicas. Becher compartió este sentimiento, reconociendo las oportunidades potenciales que se avecinan para Qualigen.
Qualigen Therapeutics, Inc. (NASDAQ: QLGN)는 2024년 9월 26일에 중대한 경영 변화를 발표했습니다. Michael Poirier는 CEO 및 이사회 의장에서 사임하였고, Christopher Lotz는 CFO에서 물러났습니다. 두 사람의 사임은 회사의 미래 방향과 전략적 이니셔티브에 대한 의견 불일치 때문이었습니다.
이사회는 9월 25일에 Campbell Becher를 대통령으로 임명하였고, 9월 26일에 Kevin Richardson을 임시 CEO 및 CFO이자 이사회 멤버로 임명했습니다. 작은 기업에서 전략적 및 구조조정 노력을 이끈 경험이 있는 Richardson은 새로운 전략적 이니셔티브를 통해 주주 가치를 증가시키는 것에 대한 기대감을 표명했습니다. Becher는 Qualigen의 앞날에 있는 잠재적 기회를 인정하며 이 같은 감정을 공감했습니다.
Qualigen Therapeutics, Inc. (NASDAQ: QLGN) a annoncé des changements significatifs dans la direction le 26 septembre 2024. Michael Poirier a démissionné de son poste de CEO et de Président du Conseil d'Administration, tandis que Christopher Lotz a quitté son poste de CFO, les deux avec effet immédiat. Leurs démissions étaient dues à des désaccords concernant l'orientation future de l'entreprise et les initiatives stratégiques.
Le Conseil a nommé Campbell Becher Président le 25 septembre, et Kevin Richardson CEO et CFO par intérim, ainsi que membre du Conseil, le 26 septembre. Richardson, connu pour son expérience dans la conduite d'efforts stratégiques et de redressement dans les petites entreprises, a exprimé son enthousiasme à l'idée d'améliorer la valeur pour les actionnaires grâce à de nouvelles initiatives stratégiques. Becher a partagé ce sentiment, reconnaissant les opportunités potentielles qui se présentent pour Qualigen.
Qualigen Therapeutics, Inc. (NASDAQ: QLGN) gab am 26. September 2024 bedeutende Veränderungen im Management bekannt. Michael Poirier trat als CEO und Vorsitzender des Vorstands zurück, während Christopher Lotz als CFO zurücktrat, beide mit sofortiger Wirkung. Ihre Rücktritte waren auf Meinungsverschiedenheiten über die zukünftige Ausrichtung des Unternehmens und strategische Initiativen zurückzuführen.
Der Vorstand ernannte Campbell Becher am 25. September zum Präsidenten und Kevin Richardson am 26. September zum Interims-CEO und CFO sowie zum Vorstandsmitglied. Richardson, bekannt für seine Erfahrung in der Leitung strategischer und Sanierungsmaßnahmen in Unternehmen mit kleiner Marktkapitalisierung, äußerte seine Begeisterung, den Aktionärswert durch neue strategische Initiativen zu steigern. Becher teilte dieses Gefühl und erkannte die potenziellen Chancen, die Qualigen bevorstehen.
- Appointment of experienced leadership with Kevin Richardson as Interim CEO and CFO
- New management team focused on enhancing shareholder value
- Potential for new strategic initiatives to drive company growth
- Sudden resignation of both CEO and CFO due to strategic disagreements
- Potential disruption in company operations due to abrupt leadership change
- Uncertainty regarding the company's future direction
CARLSBAD, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced on September 23, 2024, Mr. Michael Poirier, notified the board of directors of the Company (the Board") of his intention to resign as chief executive officer and Chairman of the Board of the Company, effective immediately. On the same date, Mr. Christopher Lotz, Chief Financial Office also tendered his resignation from the company, effective immediately. Both resignations were attributed to disagreements with the Company regarding its future direction and strategic initiatives.
On September 25, 2024, the board of directors appointed Campbell Becher as President of the Company, effective immediately.
On September 26, 2024, the board of directors appointed Kevin Richardson as Interim Chief Executive Officer and Chief Financial Officer as well as a member of the board of directors. Mr. Richardson has extensive experience in leading strategic and turnaround efforts in various small cap companies. “I am excited to be given the opportunity to lead Qualigen as it embarks on new strategic initiatives that will enhance shareholder value”. Mr. Richardson most recently served as CEO of Sanuwave Health Inc., a medical device startup that Mr. Richardson took from a fledgling operation to
New President Campbell Becher shares Mr. Richardson’s enthusiasm for the future. “We are entering an exciting time at Qualigen with many potential opportunities ahead. We would like to thank Michael and Chris for their years of leadership and guidance at Qualigen.”
About Qualigen Therapeutics, Inc.
For more information about Qualigen Therapeutics, Inc., please visit www.qlgntx.com.
Forward-Looking Statements
This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company may in some cases use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. The Company’s forward-looking statements are based on current beliefs and expectations of its management team that involve risks, potential changes in circumstances, assumptions, and uncertainties, including statements regarding the timing of the offering. Any or all of the forward-looking statements may turn out to be wrong or be affected by assumptions the Company makes that later turn out to be incorrect, or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including risks related to the Company’s ability to regain compliance with Nasdaq’s continued listing requirements, including the Company’s ability to file its Form 10-Q for the period ended September 30, 2024, or otherwise in the future, or otherwise maintain compliance with any other listing requirement of The Nasdaq Capital Market, the potential de-listing of the Company’s shares from The Nasdaq Capital Market due to its failure to comply with the Nasdaq’s continued listing requirement, or its alternatives, or otherwise in the future, and the other risks set forth in the Company’s filings with the Securities and Exchange Commission, including in its Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q. For all these reasons, actual results and developments could be materially different from those expressed in or implied by the Company’s forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this news release. The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
Investor Relations
ir@qlgntx.com.
Source: Qualigen Therapeutics, Inc.
FAQ
Why did Qualigen Therapeutics (QLGN) CEO and CFO resign?
Who are the new leaders appointed at Qualigen Therapeutics (QLGN)?
What is Kevin Richardson's background before joining Qualigen Therapeutics (QLGN)?
When did the management changes at Qualigen Therapeutics (QLGN) take effect?
